Body mass index (BMI) and abdominal circumference (waistline) also were reduced, while all three measures were unchanged in untreated control monkeys. Imaging studies also showed a substantial decrease in body fat among treated animals.
“Development of this compound for human use would provide a non-surgical way to actually reduce accumulated white fat, in contrast to current weight-loss drugs that attempt to control appetite or prevent absorption of dietary fat,” said co-senior author Renata Pasqualini, Ph.D., professor in MD Anderson’s David H. Koch Center for Applied Research of Genitourinary Cancers.
Science Translational Medicine - A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
Obesity, defined as body mass index greater than 30, is a leading cause of morbidity and mortality and a financial burden worldwide. Despite significant efforts in the past decade, very few drugs have been successfully developed for the treatment of obese patients. Biological differences between rodents and primates are a major hurdle for translation of anti-obesity strategies either discovered or developed in rodents into effective human therapeutics. Here, we evaluate the ligand-directed peptidomimetic CKGGRAKDC-GG-D(KLAKLAK)2 (henceforth termed adipotide) in obese Old World monkeys. Treatment with adipotide induced targeted apoptosis within blood vessels of white adipose tissue and resulted in rapid weight loss and improved insulin resistance in obese monkeys. Magnetic resonance imaging and dual-energy x-ray absorptiometry confirmed a marked reduction in white adipose tissue. At experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function. Together, these data in primates establish adipotide as a prototype in a new class of candidate drugs that may be useful for treating obesity in humans.
Monkeys are spontaneously obese. In earlier preclinical research, obese mice lost about 30 percent of their body weight with the drug, now called Adipotide. The drug acts on white adipose tissue, the scientific name for the unhealthy type of fat that accumulates under the skin and around the abdomen, and is a disease and mortality predictor.
“Most drugs against obesity fail in transition between rodents and primates,” Pasqualini said. “All rodent models of obesity are faulty because their metabolism and central nervous system control of appetite and satiety are very different from primates, including humans. We’re greatly encouraged to see substantial weight loss in a primate model of obesity that closely matches the human condition.”
The rhesus monkeys in the current study were “spontaneously” obese, said study first author Kirstin Barnhart, D.V.M, Ph.D., a veterinary clinical pathologist at MD Anderson’s Keeling Center for Comparative Medicine and Research in Bastrop, Texas. No specific actions were taken to make them overweight; they became so by overeating the same foods provided to other monkeys in the colony and avoiding physical activity.
The wider problems of obesity
This primate model also shares other physiological features associated with human obesity, such as metabolic syndrome, characterized by an increased resistance to insulin, which can lead to the development of type 2 diabetes and cardiovascular disease. Adipotide-treated monkeys showed marked improvements in insulin resistance – using about 50 percent less insulin after treatment.
Arap, Pasqualini and colleagues are preparing for a clinical trial in which obese prostate cancer patients would receive daily injections of Adipotide for 28 consecutive days. “The question is, will their prostate cancer become better if we can reduce their body weight and the associated health risks,” Arap said.
Some prostate cancer treatments, such as hormone therapy, cause weight gain. Greater weight can lead to arthritis, which in turn causes inactivity that leads to more weight gain, a cascade effect of co-morbidities, Arap said. Fat cells also secrete growth hormones that cancer cells thrive upon.
Overall and abdominal body fat levels drop, with reversible renal side effects
Weight, BMI and abdominal circumference all continued to drop for three weeks after treatment ended before slowly beginning to reverse during the fourth week of the follow-up period.
Magnetic Resonance Imaging (MRI) was used to gauge abdominal body fat, thought to be the most dangerous area for humans to gain weight in terms of raising disease risk. Treated monkeys’ abdominal fat levels fell by 27 percent during the study. Fat levels increased slightly in the control group.
Lean monkeys did not lose weight in a separate study to test for potential effects of the drug in non-obese animals, indicating that the drug’s effect may be selective for obese subjects.
Monkeys in the studies remained bright and alert throughout, interacting with caretakers and demonstrating no signs of nausea or food avoidance. This is a potentially important finding since unpleasant side-effects have limited the use of approved drugs that reduce fat absorption in the intestines.
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks